Surmodics, Inc. (NASDAQ:SRDX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

SRDX has been the subject of a number of other reports. Lake Street Capital assumed coverage on Surmodics in a research report on Friday, July 14th. They set a “buy” rating and a $40.00 price target for the company. Aegis started coverage on Surmodics in a research report on Tuesday, June 27th. They issued a “buy” rating for the company. Zacks Investment Research downgraded Surmodics from a “hold” rating to a “sell” rating in a research report on Monday, May 1st. Finally, ValuEngine downgraded Surmodics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $34.33.

Shares of Surmodics (NASDAQ:SRDX) traded up 0.41% during trading on Friday, hitting $24.60. 45,948 shares of the stock were exchanged. The stock’s 50 day moving average price is $26.93 and its 200-day moving average price is $24.78. The company has a market cap of $322.48 million, a price-to-earnings ratio of 53.59 and a beta of 0.88. Surmodics has a one year low of $21.90 and a one year high of $30.75.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.09 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.10. The company had revenue of $17.80 million during the quarter, compared to the consensus estimate of $15.98 million. Surmodics had a return on equity of 7.28% and a net margin of 8.66%. Surmodics’s revenue was down 11.0% on a year-over-year basis. During the same period last year, the business posted $0.37 earnings per share. On average, analysts predict that Surmodics will post $0.27 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/12/surmodics-inc-srdx-downgraded-by-bidaskclub-to-sell.html.

In other Surmodics news, CEO Gary R. Maharaj sold 5,000 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $25.75, for a total value of $128,750.00. Following the completion of the sale, the chief executive officer now directly owns 126,807 shares of the company’s stock, valued at $3,265,280.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Bryan K. Phillips sold 1,226 shares of the firm’s stock in a transaction on Friday, June 16th. The stock was sold at an average price of $24.85, for a total value of $30,466.10. Following the completion of the sale, the senior vice president now directly owns 29,208 shares of the company’s stock, valued at $725,818.80. The disclosure for this sale can be found here. Insiders sold 14,928 shares of company stock valued at $392,469 over the last three months. Company insiders own 6.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the company. Trigran Investments Inc. increased its stake in Surmodics by 52.4% in the first quarter. Trigran Investments Inc. now owns 1,070,499 shares of the company’s stock worth $25,745,000 after buying an additional 368,212 shares in the last quarter. Wellington Management Group LLP increased its stake in Surmodics by 8.7% in the first quarter. Wellington Management Group LLP now owns 1,174,839 shares of the company’s stock worth $28,255,000 after buying an additional 94,388 shares in the last quarter. Royce & Associates LP boosted its position in shares of Surmodics by 12.2% in the first quarter. Royce & Associates LP now owns 368,092 shares of the company’s stock valued at $8,853,000 after buying an additional 40,000 shares during the period. Renaissance Technologies LLC boosted its position in shares of Surmodics by 4.0% in the first quarter. Renaissance Technologies LLC now owns 1,002,721 shares of the company’s stock valued at $24,115,000 after buying an additional 38,683 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Surmodics by 6.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 587,924 shares of the company’s stock valued at $14,933,000 after buying an additional 37,480 shares during the period. 84.83% of the stock is owned by institutional investors and hedge funds.

About Surmodics

Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.

Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.